SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E, Ulrich M, Epp A, Younan P, Sahetya D, Hensley K, Allred S, Huang LY, Hahn J, Gahnberg K, Treuting PM, Trueblood ES, Gosink JJ, Thurman R, Wo S, Spahr K, Haass EJ, Snead K, Miller D, Padilla M, Smith AJ, Frantz C, Schrum JP, Nazarenko N, Gardai SJ.
Gray E, et al. Among authors: gosink jj.
J Immunother Cancer. 2023 Oct;11(10):e007572. doi: 10.1136/jitc-2023-007572.
J Immunother Cancer. 2023.
PMID: 37793853
Free PMC article.